Vor Biopharma Inc.

NASDAQ:VOR

Biotechnology

Healthcare
$18.18 -2.26%

-$0.34 today

Market cap
$985.10M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$2,053.13
52W Low $4.28High $65.80

Volume 0.83M

Average 1.07M

VOR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Vor Biopharma Inc.NASDAQ: VOR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$219.56M, compared with -$31.66M a year earlier. Trailing-twelve-month EBITDA was $449.13M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -511.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$219.56M-112.7% QoQ
Last fiscal yearDec 2025
-$693.09M-511.3% YoY
LTMMar 2026
$449.13M+489.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-593.5%+100.0%+693.5 pp
1 year-511.3%+100.0%+611.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(693.09M) USD
Year-over-year change
-511.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How VOR compares with its peers on the latest reported figures

  • VOR's LTM Mar 2026 EBITDA of $449.13M is the highest of the 10 companies compared; the peer median is -$187.06M.
  • Its year-over-year change of +489.9% is the highest of 10, against a peer median of +10.7%.
VOR Competitors Peer median
EBITDA for VOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$449.13M +489.9%——
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$89.9M -1211.1%——
NKTXNkarta, Inc.LTM Mar 2026-$90.7M +10.7%——
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M +56.8%—258.7%
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M +23.4%—1859.1%
SANASana Biotechnology, Inc.LTM Mar 2026-$187.06M +2.3%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M +21.0%——
AUTLAutolus Therapeutics plcLTM Mar 2026-$230.8M +3.4%—249.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$384.61M +25.4%—581.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026-$482.67M -3.6%—1917.5%
Peer median (excluding VOR) -$187.06M+10.7%—581.9%

Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue08.96M3.49M00
Gross Profit0(8.96M)(3.49M)00
Gross Margin—————
Research & Development47.53M64.55M94.32M93.31M321.53M
Selling, General & Admin21.49M19.91M31.72M27.88M50.11M
Operating Expenses69.02M84.46M122.54M121.19M371.64M
Depreciation & Amortization1.43M8.96M3.49M3.53M2.89M
EBITDA(67.47M)(83.13M)(114.37M)(113.39M)(693.09M)
EBITDA Margin—————
Operating Income(69.02M)(93.42M)(126.04M)(121.19M)(371.64M)
Operating Margin—————
Interest Income119K1.32M8.17M4.27M5.87M
Interest Expense00000
Other Income / Expenses119K1.32M8.17M4.27M(324.34M)
Income Before Tax(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Net Margin—————
EPS (Basic)(37.80)(46.60)(35.00)(34.00)(70.50)
EPS (Diluted)(37.80)(46.60)(35.00)(34.00)(70.50)
Weighted Avg Shares1.86M1.98M3.36M3.44M9.87M
Weighted Avg Shares (Diluted)1.86M1.98M3.36M3.44M9.87M

Vor Biopharma Inc.

NASDAQ:VOR

Intrinsic Alpha fair value

Locked

Current Price

$18.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.